Clinical Trials Directory

Trials / Active Not Recruiting

Active Not RecruitingNCT04782375

Safely Discontinue Antiviral Treatment in Patients With Chronic Hepatitis B

A Multicenter Prospective Open-label Single Arm Trial to Safely Discontinue Antiviral Treatment in Patients With Chronic Hepatitis B With a Comparison to Matched Historical Controls (ADAPT)

Status
Active Not Recruiting
Phase
Phase 4
Study type
Interventional
Enrollment
140 (actual)
Sponsor
Asan Medical Center · Academic / Other
Sex
All
Age
19 Years – 65 Years
Healthy volunteers
Not accepted

Summary

Multicenter, Prospective Open-label Single Arm Trial Chronic hepatitis B male and female adults on antiviral treatment for hepatitis B, without cirrhosis who are currently HBV DNA (-) and HBeAg (-) To evaluate the safety and efficacy of stopping long-term antiviral therapy in chronic hepatitis B patients without cirrhosis who are currently HBV DNA (-) and HBeAg (-)

Detailed description

This clinical trial is a multicenter, Prospective Open-label Single Arm Trial to compare the short-term clinical outcome between stopping and continuing antiviral treatment in chronic hepatitis B patients without cirrhosis who are currently HBV DNA (-) and HBeAg (-) Approximately 140 subjects meeting eligibility criteria will be enrolled a Intervention Arm as below; * Intervention Arm: 140 subjects, discontinue antiviral treatment (stop group) * Historical cohort: 700 subjects, continue antiviral treatment Stop group is scheduled to be followed up to 12months. Patients in the stop group were retreated with nucleos(t)ide analogues that had been prescribed previously if they fulfill one of the following criteria: 1) HBV DNA \>2,000 IU/mL, 2) progression to liver cirrhosis, or 3) development of hepatocellular carcinoma.

Conditions

Interventions

TypeNameDescription
DRUGStop groupdiscontinue antiviral treatment

Timeline

Start date
2021-09-01
Primary completion
2024-08-19
Completion
2026-01-31
First posted
2021-03-04
Last updated
2025-10-03

Locations

9 sites across 1 country: South Korea

Source: ClinicalTrials.gov record NCT04782375. Inclusion in this directory is not an endorsement.